Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital
| Autor: | Bellis, Jennifer R, Kirkham, Jamie J, Nunn, Anthony J, Pirmohamed, Munir |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Male
Chi-Square Distribution Time Factors Adolescent Drug-Related Side Effects and Adverse Reactions Infant Newborn Infant Off-Label Use Hospitals Pediatric Tertiary Care Centers Logistic Models Patient Admission England Risk Factors Child Preschool Odds Ratio Polypharmacy Humans Female Prospective Studies Paediatric Clinical Pharmacology Child |
| Popis: | To examine the impact of off-label and unlicensed (OLUL) prescribing on adverse drug reactions (ADRs) causing unplanned admissions to a paediatric hospital.Prescription data from a 12 month prospective cohort study of ADRs detected in children admitted to a paediatric hospital were scrutinized. The relative risk for off-label and unlicensed medicines being implicated in an ADR was calculated. Logistic regression analyses were carried out with exposure to off-label and unlicensed medicines and number of off-label and unlicensed medicines administered as predictor variables.Off-label and unlicensed medicines were more likely to be implicated in an ADR than authorized medicines (relative risk 1.67, 95% CI 1.38, 2.02, P 0.001). There was a 25% increase in ADR risk (95% CI 1.16, 1.35, P 0.001) with each additional authorized medicine and 23% (95% CI 1.10, 1.36, P 0.001) with each additional off-label or unlicensed medicine. Logistic regression analysis focusing on non-oncology patients demonstrated that the number of authorized medicines (odds ratio 1.33, 95% CI 1.23, 1.44, P 0.001), but not the number of off-label and unlicensed medicine courses, was a predictor of ADR risk.In a heterogeneous population of children admitted to a secondary/tertiary hospital, off-label and unlicensed medicines are more likely to be implicated in an ADR than authorized medicines. This was largely driven by ADRs related to drugs used in oncological practice, where the usage of off-label or unlicensed medicines was associated with a higher ADR risk than in non-oncological areas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|